Status:
UNKNOWN
A Safety Study of Combination Treatment With Avonex and Placebo-Controlled Dosing of Topamax in Relapsing-Remitting Multiple Sclerosis
Lead Sponsor:
Multiple Sclerosis Institute
Conditions:
Multiple Sclerosis
Eligibility:
All Genders
18-55 years
Phase:
PHASE2
Brief Summary
This is a clinical trial in relapsing-remitting Multiple Sclerosis to determine if Topamax added to Avonex has a neuroprotective effect as measured by the brain parenchymal fraction ( a measure of bra...
Detailed Description
The protocol requires all participants to be treated with Avonex and in addition patients will be blindly assigned to either a group who receive Topamax or a placebo control. Repeated neurological and...
Eligibility Criteria
Inclusion
- Relapsing-remitting multiple sclerosis
- \-
Exclusion
- Secondary progressive multiple sclerosis Contraindication to MRI Systemic disease Pregnancy -
Key Trial Info
Start Date :
April 1 2004
Trial Type :
INTERVENTIONAL
End Date :
December 1 2007
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00217295
Start Date
April 1 2004
End Date
December 1 2007
Last Update
September 22 2005
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Multiple Sclerosis Institute
Philadelphia, Pennsylvania, United States, 19146